Changes for page Ajanta Pharma Ltd

Last modified by Asif Farooqui on 2021/03/15 15:40

From version < 3.1 >

edited by Asif Farooqui
on 2020/10/08 14:49

To version < 4.1 >

edited by Asif Farooqui
on 2020/10/08 14:51

< >

Change comment: There is no comment for this version

Summary

Page properties

Content

@@ -101,8
+101,8 @@
  **Q4 FY 2019, total export sales were Rs. 343 cr. (against Rs. 348 cr.) posting de-growth of 1%.**
  * Emerging Market branded generic sale was Rs. 221 cr. (against Rs. 243 cr.) posting 9% de-growth. Out of which:
--* Africa branded generic sale was Rs. 75 cr. (against Rs. 109 cr.) posting 31% degrowth.
--* Asia branded generic sale was Rs. 143 cr. (against Rs. 132 cr.) posting 9% growth.
++** Africa branded generic sale was Rs. 75 cr. (against Rs. 109 cr.) posting 31% degrowth.
++** Asia branded generic sale was Rs. 143 cr. (against Rs. 132 cr.) posting 9% growth.
  * US generic sale was Rs. 76 cr. (against Rs. 42 cr.) posting 79% growth.
  * Africa Institution sale was Rs. 46 cr. (against Rs. 63 cr.) posting 26% de-growth.